Sustained immune control in HBeAg-positive chronic hepatitis B patients who switched from long-term entecavir therapy to peginterferon alfa-2a (40KD): 1-year follow-up of the OSST study
单位：[1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan 430074, Peoples R China;华中科技大学同济医学院附属同济医院[2]Fujian Med Univ, Hosp 1, Fuzhou, Peoples R China;[3]Nanfang Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China;[4]Cent S Univ, Xiangya Hosp, Changsha, Hunan, Peoples R China;[5]Fourth Mil Med Univ, Tangdu Hosp, Xian 710032, Peoples R China;[6]Shanghai Roche Pharmaceut Co Ltd, Shanghai, Peoples R China
第一作者单位：[1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan 430074, Peoples R China;
推荐引用方式(GB/T 7714)：
Han Meifang,Jiang Jia-ji,Hou Jinlin,et al.Sustained immune control in HBeAg-positive chronic hepatitis B patients who switched from long-term entecavir therapy to peginterferon alfa-2a (40KD): 1-year follow-up of the OSST study[J].HEPATOLOGY.2013,58:665A-666A.
APA：
Han, Meifang,Jiang, Jia-ji,Hou, Jinlin,Tan, Deming,Sun, Yongtao...&Ning, Qin.(2013).Sustained immune control in HBeAg-positive chronic hepatitis B patients who switched from long-term entecavir therapy to peginterferon alfa-2a (40KD): 1-year follow-up of the OSST study.HEPATOLOGY,58,
MLA：
Han, Meifang,et al."Sustained immune control in HBeAg-positive chronic hepatitis B patients who switched from long-term entecavir therapy to peginterferon alfa-2a (40KD): 1-year follow-up of the OSST study".HEPATOLOGY 58.(2013):665A-666A
医学